Retreatment with rituximab alone induces sutained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab

Hematology Journal

Volumn 4, Issue 2, 2003, Pages 151-153

  Cohen, Yossi ^a   Libster, Dianna ^b   Da'as, Nael ^b   Amir, Gail ^b   Polliack, Aaron ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Follicular lymphoma; Retreatment; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; FOLLICULAR LYMPHOMA; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE BIOPSY; MAINTENANCE THERAPY; MALE; SKIN BIOPSY; SKIN LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; VIDARABINE;

EID: 0038170275     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200208     Document Type: Article

References (13)

1. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH Pate O, Younes A et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage JV indolent lymphoma. Semin Oncol 2000; 27(6 Suppl 12): 37-41.
2. Hainsworth JD, Burris 3rd HA, Morrissey LH, Litchy S, Scullin Jr DC, Bearden 3rd JD et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 15: 3052-3056.
3. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 1: 101-106.
4. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
5. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851-1857.
6. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
8. Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000; 79: 493-500.
9. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81-88.
10. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond L. WIDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76-82.
11. Horning SJ, Weiss LM, Nevitt JB, Warnke RA. Clinical and pathologic features of follicular large cell (nodular histiocytic) lymphoma. Cancer 1987; 15: 1470-1474.
12. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
13. Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M et al. IDEC-C2B8 Study Group. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73: 213-221.